63 Recruiting Studies Using Trastuzumab Deruxtecan
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Trastuzumab Deruxtecan
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
📍 Research Site — Tucson, Arizona
Triple Negative Breast Neoplasms
View Study & Checklist ➔Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
📍 Research Site — Baltimore, Maryland
Gastric Cancer
View Study & Checklist ➔Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
📍 Research Site — Springdale, Arkansas
Breast Neoplasms
View Study & Checklist ➔PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
HER2-positive Breast Cancer
View Study & Checklist ➔DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
📍 UCLA Hematology Oncology — Los Angeles, California
Breast Cancer
View Study & Checklist ➔A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
📍 Research Site — Commack, New York
Metastatic Breast Cancer
View Study & Checklist ➔Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
📍 National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
📍 Research Site — Duarte, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
📍 Research Site — Duarte, California
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
View Study & Checklist ➔Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
📍 Ironwood Cancer & Research Centers - Chandler II — Chandler, Arizona
Breast Cancer
View Study & Checklist ➔A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
📍 Research Site — Boston, Massachusetts
Breast Cancer
View Study & Checklist ➔A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
📍 Research Site — Fort Myers, Florida
Metastatic Breast Cancer
View Study & Checklist ➔A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
📍 Research Site — Santa Rosa, California
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
View Study & Checklist ➔Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
📍 Research Site — Scottsdale, Arizona
Advanced or Metastatic Breast Cancer
View Study & Checklist ➔Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
📍 Weill Cornell Medicine/New York-Presbyterian — New York, New York
Esophageal Adenocarcinoma
View Study & Checklist ➔Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Breast Cancer
View Study & Checklist ➔DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
📍 Univ. of Cali. San Francisco Medical Center — San Francisco, California
Breast Cancer
View Study & Checklist ➔Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
📍 Research Site — Tucson, Arizona
Breast Cancer; HER2-positive; Metastatic
View Study & Checklist ➔Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
Advanced Breast Carcinoma
View Study & Checklist ➔A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
📍 Research Site — Anchorage, Alaska
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
View Study & Checklist ➔Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
📍 Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
Breast Cancer
View Study & Checklist ➔Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
📍 Washington University School of Medicine — St Louis, Missouri
Breast Cancer
View Study & Checklist ➔ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
📍 MD Anderson Cancer Center — Houston, Texas
Dynamic Tumor Resistance
View Study & Checklist ➔Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers
📍 UT MD Anderson — Houston, Texas
Breast Cancer
View Study & Checklist ➔Scalp Cooling in MBC
📍 Brigham and Women's Hospital — Boston, Massachusetts
Metastatic Breast Cancer
View Study & Checklist ➔Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Metastatic Salivary Gland Carcinoma
View Study & Checklist ➔Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
📍 Moffitt Cancer Center — Tampa, Florida
Metastatic Breast Cancer
View Study & Checklist ➔DESTINY-PANTUMOUR04
📍 Research Site — Birmingham, Alabama
Adenocarcinoma (NOS)
View Study & Checklist ➔Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
📍 Yale Cancer Center — New Haven, Connecticut
Gastric Cancer
View Study & Checklist ➔An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
📍 City of Hope Medical Center — Duarte, California
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist ➔A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
📍 University of Michigan (Data Collection Only) — Ann Arbor, Michigan
Non-Small Cell Lung Cancer
View Study & Checklist ➔A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
📍 Southern Cancer Center (SCC) ( Site 8000) — Daphne, Alabama
Breast Neoplasms
View Study & Checklist ➔Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
📍 Alaska Oncology & Hematology, LLC — Anchorage, Alaska
Non-small Cell Lung Cancer
View Study & Checklist ➔Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Metastatic Malignant Solid Neoplasm
View Study & Checklist ➔Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
Locally Advanced Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
📍 The Oncology Institute of Hope and Innovation — Cerritos, California
Metastatic Breast Cancer
View Study & Checklist ➔A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
Advanced Solid Tumor
View Study & Checklist ➔DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
📍 Research Site — Tucson, Arizona
Endometrial Cancer
View Study & Checklist ➔TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
📍 University of Alabama — Birmingham, Alabama
Breast Cancer
View Study & Checklist ➔Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Anatomic Stage III Breast Cancer AJCC v8
View Study & Checklist ➔Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
📍 University of Texas Health Science Center at San Antonio — San Antonio, Texas
Solid Tumor
View Study & Checklist ➔A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
📍 Research Site — Newark, Delaware
Gastroesophageal Adenocarcinoma
View Study & Checklist ➔Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
📍 Yale Cancer Center — New Haven, Connecticut
Metastatic Breast Cancer
View Study & Checklist ➔Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
📍 Children's Hospital of Alabama — Birmingham, Alabama
Desmoplastic Small Round Cell Tumor
View Study & Checklist ➔The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Breast Cancer Female
View Study & Checklist ➔A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
📍 Research Site — Anchorage, Alaska
HER2-positive Gastric Cancer
View Study & Checklist ➔TRUDI: TDXD+Durva in HER2+/Low IBC
📍 Brigham and Women's Hospital — Boston, Massachusetts
Invasive Breast Cancer
View Study & Checklist ➔Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
📍 UT MD Anderson Cancer Center — Houston, Texas
Clinical Stage III Gastric Cancer AJCC v8
View Study & Checklist ➔A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
📍 Research Site — Newport Beach, California
Recurrent or Metastatic Solid Tumors
View Study & Checklist ➔Trial of Trastuzumab Deruxtecan in Previously Treated HER2
📍 Yale University — New Haven, Connecticut
Breast Cancer Metastatic
View Study & Checklist ➔Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
📍 Research Site — Scottsdale, Arizona
Biliary Tract Cancer
View Study & Checklist ➔Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
📍 Mount Sinai Medical Center — Miami Beach, Florida
Breast Cancer
View Study & Checklist ➔EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
📍 MD Anderson Cancer Center — Houston, Texas
Advanced Solid Tumor
View Study & Checklist ➔Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
📍 St. Joseph Heritage Healthcare — Fullerton, California
Early-stage Breast Cancer
View Study & Checklist ➔ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Metastatic Breast Cancer
View Study & Checklist ➔Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Metastatic Malignant Solid Neoplasm
View Study & Checklist ➔Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
📍 Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
Brain Cancer
View Study & Checklist ➔FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
📍 University of Arizona - Cancer Center — Tucson, Arizona
Urinary Bladder Neoplasms
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
📍 City of Hope — Duarte, California
Metastatic Breast Cancer
View Study & Checklist ➔Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
📍 Disney Family Cancer Center — Burbank, California
Ovarian Cancer
View Study & Checklist ➔Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
📍 Broward Health Medical Center — Fort Lauderdale, Florida
Endometrial Cancer
View Study & Checklist ➔Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
📍 Research Site — La Jolla, California
Advanced Solid Malignancies
View Study & Checklist ➔Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔